Acknowledgements
TIA, NBF, ®
WRIGHT, TIA
The authors wish to thank all the study volunteer participants. We acknowledge VIRGo research nurses and doctors: Lani Shiels, Janet Briggs, Clare Brophy, Megan Hocking, Annmarie McEvoy, Dima El Sukkari, and Marita Nolan; Royal Melbourne Hospital (RMH) research nurse Joanne Patterson in the lower dose sentinel stage; Hayley Page and Helen Kent (Kent group); RMH Pharmacy (Clinical Trials Group) who managed study IP; staff of Southern Star Research who were contracted to act as the CRO for data management and monitoring. We thank our COVID Vaccine Advisory Panel: Manon Cox, Peter Dull, John McEwen, Kim Wright, and Mike Levine. Additional scientific and regulatory advice was provided by Mark Sullivan, Jim Ackland, James McCluskey, and Gary Grohmann. We thank DSMB members Jim Buttery, Jo-Anne Grey, Sue Lee, and Peter Richmond.Many others provided valuable input into vaccine manufacture, quality assurance, documentation: Trent Munro (University of Queensland) and Jillian Bennet (Tanawell Consulting); from CSIRO Judith Scoble, John Power, Pat Pilling, Susie Nilsson, and Tram Phan; Drew Brockman and Peter Tapley (Agilex Biolabs); Marianne Gillard, Kym Hoger, Karen Hughes, Ben Hughes, Martina Jones, Paul Young and Keith Chappell (University of Queensland); Lena Miloradovic, Jenny Herz, Fiona Seddon, Denison Chang and Patricia Vietheer (Biointelect). We acknowledge provision of facilities, and scientific and technical assistance of the National Biologics Facility (NBF) whose University of Queensland node and CSIRO node are supported by Therapeutic Innovation Australia (TIA), and the Australian Government through the National Collaborative Research Infrastructure Strategy program. We thank CSL Seqirus for donating the MF59® adjuvant.Funding: Supplementary data related to this article can be found at 